Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions-Reference-Cited by-同舟云学术

Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions

Published:2020-12 Issue:12 Volume:21 Page:e575-e588
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Bennett Charles L,Schoen Martin W,Hoque Shamia,Witherspoon Bartlett J,Aboulafia David M,Hwang Catherine S,Ray Paul,Yarnold Paul R,Chen Brian K,Schooley Benjamin,Taylor Matthew A,Wyatt Michael D,Hrushesky William J,Yang Y Tony

Publisher

Elsevier BV

Subject

Oncology

Reference40 articles.

1. Regulatory and clinical considerations for biosimilar oncology drugs;Bennett;Lancet Oncol,2014

2. Postmarket policy considerations for biosimilar oncology drugs;Renwick;Lancet Oncol,2016

3. Biosimilars: the US regulatory framework;Christl;Annu Rev Med,2017

4. Biosimilars in oncology in the United States: a review;Nabhan;JAMA Oncol,2018

5. Systematic approach to pharmacovigilance beyond the limits: the Southern Network on Adverse Reactions (SONAR) projects;Lu;Adv Pharmacoepidemiol Drug Saf,2014

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Noninferiority Assessment of Two Filgrastim Biosimilars in Patients Receiving Myelosuppressive Chemotherapy;JCO Oncology Practice;2024-07-24

2. Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective;Journal of Medical Economics;2024-07-23

4. A descriptive analysis of real-world oncology biosimilar use in Japan;Future Oncology;2024-06-12

5. Monoclonal antibody biosimilars for cancer treatment;iScience;2024-06